Skip to main content

United States News All stories

Every story in this section, newest first — page 222 of 373.

Grafa

Aligos Therapeutics secures $445M licensing deal with Amoytop for HBV candidate in China

Aligos Therapeutics (NASDAQ:ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for viral and liver diseases, announced on April 16, 2026, that it has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech.

Read more: Aligos Therapeutics secures $445M licensing deal with Amoytop for HBV candidate in China